Gemcitabine enhances the Cisplatin-induced inhibition of cell viability. The anti-cancer drug sensitivity in the Caov-3 (A), A2780CP (B) and A2780 (C) cells was examined using an MTS assay. The cells were treated with the indicated concentrations of Cisplatin with or without 100 nM of Gemcitabine (GEM). Twenty-four hours later, the cell viability was assessed using the MTS assay as described under “Materials and Methods”. Significant differences are indicated by asterisks. **, p < 0.01.